Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 313

1.
2.

Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.

Mueller JJ, Zhou QC, Iasonos A, O'Cearbhaill RE, Alvi FA, El Haraki A, Eriksson AG, Gardner GJ, Sonoda Y, Levine DA, Aghajanian C, Chi DS, Abu-Rustum NR, Zivanovic O.

Gynecol Oncol. 2016 Mar;140(3):436-42. doi: 10.1016/j.ygyno.2016.01.008. Epub 2016 Jan 9.

3.

Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.

Shen Y, Li L.

Tumour Biol. 2016 Nov;37(11):14765-14772. Epub 2016 Sep 15.

PMID:
27629144
4.

Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.

Gill SE, McGree ME, Weaver AL, Cliby WA, Langstraat CL.

Gynecol Oncol. 2017 Feb;144(2):266-273. doi: 10.1016/j.ygyno.2016.11.021. Epub 2016 Dec 1.

PMID:
27916269
5.

Neoadjuvant chemotherapy or primary debulking surgery in FIGO IIIC and IV patients; results from a survey study in the Netherlands.

Timmermans M, Sonke GS, van Driel WJ, Lalisang RI, Ottevanger PB, de Kroon CD, Van de Vijver KK, van der Aa MA, Kruitwagen RF.

Eur J Obstet Gynecol Reprod Biol. 2018 Apr;223:98-102. doi: 10.1016/j.ejogrb.2018.02.029. Epub 2018 Mar 6.

PMID:
29525755
6.

Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.

Morrison J, Haldar K, Kehoe S, Lawrie TA.

Cochrane Database Syst Rev. 2012 Aug 15;(8):CD005343. doi: 10.1002/14651858.CD005343.pub3. Review.

7.

Outcome of Epithelial Ovarian Cancer: Time for Strategy Trials to Resolve the Problem of Optimal Timing of Surgery.

Van de Putte G, Oben J, Prenen L, Schobbens JC, Vlasselaer J, Van Holsbeke C, Debrock G, Van Eycken P, de Jonge E.

Int J Gynecol Cancer. 2015 Jul;25(6):993-9. doi: 10.1097/IGC.0000000000000461.

PMID:
25914962
8.

Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.

Vergote I, Coens C, Nankivell M, Kristensen GB, Parmar MKB, Ehlen T, Jayson GC, Johnson N, Swart AM, Verheijen R, McCluggage WG, Perren T, Panici PB, Kenter G, Casado A, Mendiola C, Stuart G, Reed NS, Kehoe S; EORTC; MRC CHORUS study investigators.

Lancet Oncol. 2018 Dec;19(12):1680-1687. doi: 10.1016/S1470-2045(18)30566-7. Epub 2018 Nov 6. Erratum in: Lancet Oncol. 2019 Jan;20(1):e10.

PMID:
30413383
9.

Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602.

Onda T, Satoh T, Saito T, Kasamatsu T, Nakanishi T, Nakamura K, Wakabayashi M, Takehara K, Saito M, Ushijima K, Kobayashi H, Kawana K, Yokota H, Takano M, Takeshima N, Watanabe Y, Yaegashi N, Konishi I, Kamura T, Yoshikawa H; Japan Clinical Oncology Group.

Eur J Cancer. 2016 Sep;64:22-31. doi: 10.1016/j.ejca.2016.05.017. Epub 2016 Jun 17.

PMID:
27323348
10.

Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer.

Vergote I, Amant F, Kristensen G, Ehlen T, Reed NS, Casado A.

Eur J Cancer. 2011 Sep;47 Suppl 3:S88-92. doi: 10.1016/S0959-8049(11)70152-6. Review.

PMID:
21944035
11.
12.

Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter?

Markauskas A, Mogensen O, dePont Christensen R, Jensen PT.

Int J Gynecol Cancer. 2014 Oct;24(8):1420-8. doi: 10.1097/IGC.0000000000000241.

PMID:
25180461
13.

Laparoscopy to predict the result of primary cytoreductive surgery in advanced ovarian cancer patients (LapOvCa-trial): a multicentre randomized controlled study.

Rutten MJ, Gaarenstroom KN, Van Gorp T, van Meurs HS, Arts HJ, Bossuyt PM, Ter Brugge HG, Hermans RH, Opmeer BC, Pijnenborg JM, Schreuder HW, Schutter EM, Spijkerboer AM, Wensveen CW, Zusterzeel P, Mol BW, Kenter GG, Buist MR.

BMC Cancer. 2012 Jan 20;12:31. doi: 10.1186/1471-2407-12-31.

14.

Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.

Kobal B, Noventa M, Cvjeticanin B, Barbic M, Meglic L, Herzog M, Bordi G, Vitagliano A, Saccardi C, Skof E.

Radiol Oncol. 2018 Sep 11;52(3):307-319. doi: 10.2478/raon-2018-0030.

15.

[Advanced ovarian cancer: primary debulking (PDS) or neoadjuvant chemotherapy (NACT) - still a debate].

Segev Y, Gemer O, Auslender R, Lavie O.

Harefuah. 2014 Sep;153(9):527-31, 558. Review. Hebrew.

PMID:
25417489
16.

Clinical study of a CT evaluation model combined with serum CA125 in predicting the treatment of newly diagnosed advanced epithelial ovarian cancer.

Qin L, Huang H, Chen M, Liang Y, Wang H.

J Ovarian Res. 2018 Jun 18;11(1):49. doi: 10.1186/s13048-018-0422-z.

17.

Serum CA 125 Level after Neoadjuvant Chemotherapy is Predictive of Prognosis and Debulking Surgery Outcomes in Advanced Epithelial Ovarian Cancer.

Matsuhashi T, Takeshita T, Yamamoto A, Kawase R, Yamada T, Kurose K, Doi D, Konnai K, Onose R, Kato H.

J Nippon Med Sch. 2017;84(4):170-176. doi: 10.1272/jnms.84.170.

18.

Primary debulking surgery vs. interval debulking surgery for advanced ovarian cancer: review of the literature and meta-analysis.

Chiofalo B, Bruni S, Certelli C, Sperduti I, Baiocco E, Vizza E.

Minerva Med. 2019 Aug;110(4):330-340. doi: 10.23736/S0026-4806.19.06078-6. Epub 2019 May 6. Review.

PMID:
31081304
19.

Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer.

Rauh-Hain JA, Rodriguez N, Growdon WB, Goodman AK, Boruta DM 2nd, Horowitz NS, del Carmen MG, Schorge JO.

Ann Surg Oncol. 2012 Mar;19(3):959-65. doi: 10.1245/s10434-011-2100-x. Epub 2011 Oct 13.

PMID:
21994038
20.

What Should We Expect After a Complete Cytoreduction at the Time of Interval or Primary Debulking Surgery in Advanced Ovarian Cancer?

Chiva L, Lapuente F, Castellanos T, Alonso S, Gonzalez-Martin A.

Ann Surg Oncol. 2016 May;23(5):1666-73. doi: 10.1245/s10434-015-5051-9. Epub 2015 Dec 29.

PMID:
26714955

Supplemental Content

Support Center